States sue to block 23andMe's sale of genetic data to Regeneron without customer consent.

Twenty-seven states and the District of Columbia have filed a lawsuit to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit targets a proposed $256 million sale to Regeneron Pharmaceuticals, arguing that sensitive data like DNA and health records should not be sold without explicit consent. Regeneron promises to comply with 23andMe's privacy policies, but a court-appointed privacy ombudsman will review the deal's impact on consumer privacy.